1 / 5

Supplementary Figure 1

Supplementary Figure 1. Similar results to those showed in Figure 3B are depicted but at a different DC:MLR ratio (1:128). Supplementary Figure 2. n.s. n.s. The involvement of TGF-b and iNOS in Tol-DC immunomodulatory properties was studied in vitro . The

harmon
Download Presentation

Supplementary Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplementary Figure 1 Similar results to those showed in Figure 3B are depicted but at a different DC:MLR ratio (1:128)

  2. Supplementary Figure 2 n.s. n.s. The involvement of TGF-b and iNOS in Tol-DC immunomodulatory properties was studied in vitro. The nitric oxyde synthase inhibitor L-NMMA and its inactive control molecule, D-NMMA were added to cultures containing a naif MLR and NHP Tol-DC (1:64 ratio). A neutralizing anti-TGF-b antibody (2G7 clon) and control mouse IgG were also added to the cultures and responder T cells proliferation was studied. Neither iNOS inhibition nor TGF-b blockade were able to impair Tol-DC-induced inhibition of T cell proliferation. Ns = non significant, numbers in the graphic indicate the p value.

  3. Supplementary Figure 3 n.s. *** * The involvement of IL-10 in Tol-DC immunomodulatory properties was studied in vitro. An anti-IL-10 antibody was added to cultures containing a naif MLR and NHP Tol-DC (1:64 ratio). In contrast to HO-1 inhibition (SnPP treatment), IL-10 blockade was not able to impair Tol-DC-induced inhibition of T cell proliferation. ns = non significant; * = p<0.05; *** = p<0.001

  4. Supplementary Figure 4 Untreated LPS SnPP LPS + SnPP 40 14 42 11 CD80 MHC II 7 15 7 16 CD86 MHC II HO-1 inhibition does not modify rat BMDC expression of neither costimulatory molecules nor MHC class II. BMDC were treated during 48 hs with the indicated compounds (SnPP: HO-1 inhibitor). Numbers in the graphics represent the percentage of double positive cells. n=3.

  5. Supplementary Figure 5 64 DDAO DDAO 69 without IL-2 + IL-2 18 Untreated SnPP 22 Rat BMDC do not expand CD4+CD25+ Treg. Treg were cultured with allogeneic untreated BMDC or pulsed 2h with SnPP at 37°C. A three day culture was performed in the absence (left panel) or presence (right panel) of 50 U/ml IL-2. CD4+CD25+ proliferation was studied by FACS through analysis of the dilution of the fluorogenic probe DDAO. The numbers in the graphics represent the percentage of non-dividing cells. n=3

More Related